Ginsenoside Rb1 (Rb1) oral supplementation ameliorated dyslipidemia, improved insulin sensitivity in HFD-induced obese mice, and reversed the expression of uncoupling protein 2 (UCP2), Nuclear receptor subfamily one group H member 4 (Nr1h4), and Fiaf. Here, NR1H4 is linked to metabolic syndrome.